Skip to main
DRTS
DRTS logo

DRTS Stock Forecast & Price Target

DRTS Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Alpha Tau Medical has made a significant operational advancement by securing a radioactive material license from the New Hampshire Bureau of Public Health Protection, which aligns with the completion of its commercial-scale manufacturing facility in Hudson, NH. This development is expected to facilitate the company's entry into the U.S. market, thereby enhancing its revenue potential beyond its primary base in Israel. Furthermore, the unique capabilities of the Alpha DaRT technology demonstrate promise in addressing unmet needs in oncology and potentially triggering systemic responses, reinforcing the positive outlook for the company’s future prospects.

Bears say

Alpha Tau Medical faces significant risks that could adversely affect its stock, primarily relating to the clinical viability of its AlphaDaRT technology. The potential for failure in clinical trials and the inability to secure regulatory approval in the U.S. presents substantial obstacles to the company's success. Additionally, market limitations, competitive pressures, and the risk of shareholder dilution further exacerbate the uncertainty surrounding Alpha Tau Medical's financial outlook.

DRTS has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Alpha Tau Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Alpha Tau Medical (DRTS) Forecast

Analysts have given DRTS a Strong Buy based on their latest research and market trends.

According to 1 analysts, DRTS has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Alpha Tau Medical (DRTS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.